PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus

The checkpoint protein programmed cell death ligand-1 protein (PD-L1) binds to its receptor (PD 1) activating the PD-Ll/PD-1 pathway, an important therapeutic target. There is limited information regarding PD-Ll and PD-1 expression in thymic lesions. Sections from nonneoplastic thymi (n = 20), thymomas World Health Organization types A, AB, B1, B2, and B3 (n = 38) and thymic squamous cell carcinoma (n 8) were stained for PD-Ll (clone SP142; Spring BioScience), PD-1 (MRQ22; Cell Marque), CD4 (clone SPO32; Cell Marque),.and CD8 (JCB117; Ventana). Immunoreactivity for each antibody was classified as focal or diffuse and scored as follows: 0, negative; 1%-5%, 1+; 6%-20%, 2+; and > 20%, 3+. The proportions of cases expressing PD-L1, PD-1, CD4, and C8 at score >= 1+ were compared by diagnosis, using statistics. PD-Ll was expressed in 90% of nonneoplastic thymi, 92% of thymomas, and 50% of carcinomas, with significantly higher scores (P < .01) in B2 and B3 thymomas and carcinomas than in AB and B1 thymomas; PD-L1 was diffuse in most B2 and B3 thymomas and focal in carcinomas. PD-1 was focally expressed, and mostly with scores 1+, in 55% of nonneoplastic thymi, 63% of thymomas, and 37.5% of carcinomas. CD4+ and CD8+ cells were diffusely distributed with scores 3+ in all lesions other than B3 thymomas and carcinomas. The latter showed CD4+ cells mostly at the interface between neoplastic cells and stroma. PD-Ll and PD-1 are not expressed in similar locations and cellular proportions in thymic lesions, raising a question as to whether the PD-Ll/PD-1 pathway is an actionable therapeutic target in these lesions. (C) 2016 Elsevier Inc. All rights reserved.